BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

WuXi Biologics Partners with InflaRx to Advance Gohibic for Critically Ill COVID-19 Patients

WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody. InflaRx received emerge...

May 17, 2023 | News

Boan Biotech's BA1202 Approved for Clinical Trial

Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evalua...

May 17, 2023 | News

Antengene Announces NDA Submission for XPOVIO® in Indonesia

"In just six months, we have submitted NDAs for XPOVIO® in three ASEAN countries, Malaysia, Thailand and Indonesia, supporting...

May 17, 2023 | News

MGI Enables Completion of 60,000 Samples for Million Microbiome of Humans Project

The project was launched as a joint effort by the Karolinska Institute of Sweden, Shanghai National Clinical Research Center for Metabolic D...

May 16, 2023 | News

Rona Therapeutics and Keymed Biosciences Collaborate on siRNA Therapeutics for Glomerulonephritis

Under the term of the collaboration, Rona will use proprietary RAZOR™ platform to discover and identify siRNA lead compounds directed to a novel targ...

May 16, 2023 | News

Innovent's IBI351 gets NMPA breakthrough designation for advanced colorectal carcinoma

This BTD for IBI351 was based on the pooled analysis of two ongoing clinical trials (NCT05005234, NCT05497336), which include 54 CRC pa...

May 15, 2023 | News

Crystal Formulation Services' GMP facility passes remote US audit, marks global expansion milestone.

The audit was focused to confirm that the GMP manufacturing facility of CFS meets the US GMP regulations, and to ensure the compliance in manufacturing and...

May 15, 2023 | News

LaNova licenses novel cancer drug to AstraZeneca

LaNova Medicines Ltd. ("LaNova Medicines") announced it has entered into an exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), for LM-305,...

May 15, 2023 | News

China's Guangzhou hosts Golden Age Single-Cell and Spatial Omics Conference

The conference brings together on site over 2,000 professionals from academia, research and development, investment and other fields interested to the conf...

May 09, 2023 | News

Biosion shares Anti-CD40 Agonistic Antibody discovery and development data at PEGS

BSI-038 is an anti-CD40 agonistic monoclonal antibody, discovered through Biosion's H³ antibody discovery platform. BSI-038 exhibits enhanced bin...

May 09, 2023 | News

Ascletis approved for Phase IIa clinical trial of ASC10 for RSV infection in China

--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Do...

May 09, 2023 | News

Neuro3 Therapeutics obtains global rights for KCNQ2 activators from Lundbeck

The agreement focuses on activators of KCNQ2, an ion channel that has been clinically validated as a target for the treatment of epilepsy. Clinical findin...

May 09, 2023 | Opinion

Bliss Biopharmaceutical Collaborates with Eisai for Clinical Trial of BB-1701 with Strategic Option

This collaboration with Eisai is an important advancement in BlissBio's corporate development plan to further develop BB-1701 globally and help advance BB-...

May 08, 2023 | News

GenAssist's GEN6050 Base Editing Product Submits Pre-IND Application to FDA

Suzhou GenAssist Therapeutic Co.,Ltd recently announced its pre-IND application of their first base editing product, GEN6050 and the acceptance by the FDA....

May 08, 2023 | News

Stay Connected